Clinical trials: Gastrointestinal and Digestive Disorder
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.
- Trial name
- FORTITUDE-102 (NCT05111626)
- Testing
- Bemarituzumab, Nivolumab, Chemotherapy
- Where
- 348 sites in United States, Argentina and 27 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Crohn's Disease
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol…
- Trial name
- NCT00195715
- Testing
- Adalimumab
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 777 people
- Sponsor
- Abbott
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Crohn's Disease
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease.
- Trial name
- NCT00032799
- Testing
- natalizumab
- Where
- United States
- Volunteers
- 905 people
- Sponsor
- Biogen
Hepatocellular Carcinoma
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome…
- Trial name
- NCT04712643
- Testing
- Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE)
- Where
- 40 sites in China, Japan
- Volunteers
- 342 people
- Sponsor
- Hoffmann-La Roche
Rectal Neoplasms
Oxaliplatin in Rectal Cancer
Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study Phase II: To determine the treatment efficacy according to response rates from phase I.
- Trial name
- NCT00259363
- Testing
- Oxaliplatin
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Sanofi
Cholecystitis
Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg
Primary objective of the study: evaluation of the effect of food intake on the bioavailability of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) after a single oral administration on an empty stomach and after a meal, at a dose of…
- Trial name
- NCT06342804
- Testing
- 4-MUST, 2 tablets, fasted, 4-MUST, 2 tablets, after meals
- Where
- Russia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) in non-end-stage primary sclerosing cholangitis (PSC) participants with underlying inflammatory bowel disease (IBD).
- Trial name
- NCT03035058
- Testing
- Vedolizumab
- Sponsor
- Takeda
Chronic Hepatitis C
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
- Trial name
- NCT00722358
- Testing
- BMS-650032
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard weight based ribavirin (investigational treatment arm) or placebo in combination with…
- Trial name
- NCT00990938
- Testing
- IMO-2125, Saline
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Gastroenteritis
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
The purpose of this study is to demonstrate that domperidone suspension plus oral rehydration therapy (ORT) is more effective than placebo plus ORT at reducing the symptoms of vomiting associated with acute gastroenteritis (AG)…
- Trial name
- NCT02699385
- Testing
- Oral Rehydration Therapy, Domperidone
- Where
- 29 sites in Austria, Belgium and 4 more
- Volunteers
- 10 people
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C
Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)
This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of uprifosbuvir (MK-3682/IDX21437) in healthy participants and in participants infected with Hepatitis C virus (HCV) genotype (GT)1-GT6.
- Trial name
- NCT01974687
- Testing
- Uprifosbuvir, Itraconazole
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis, Non-alcoholic Fatty Liver Disease
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study was to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic…
- Trial name
- pINPOINt (NCT04237116)
- Testing
- Investigational Arm - secukinumab
- Where
- 8 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00372385
- Testing
- Ribavirin, Pegylated Interferon Alfa 2a, Telaprevir
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 334 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Irritable Colon
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
- Trial name
- NCT00101985
- Testing
- talnetant
- Where
- 135 sites in United States, Australia and 8 more
- Volunteers
- 741 people
- Sponsor
- GlaxoSmithKline
Pancreatic Neoplasms, Metastases, Neoplasm
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas.
- Trial name
- NCT00035035
- Testing
- GEMZAR, ALIMTA
- Where
- 114 sites in United States, Argentina and 16 more
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single…
- Trial name
- NCT07869225
- Testing
- EQ504
- Where
- Australia
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Equillium
Colorectal Cancer
A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation.
- Trial name
- INAVO-CRC (NCT07323576)
- Testing
- Inavolisib, Bevacizumab, FOLFOX
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Hepatoma
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2 expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor activity of intravenous TKM-080301 in subjects with…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Adult
- Trial name
- NCT02191878
- Testing
- TKM-080301
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.